Biocon Expects US b(Humira) Market To Consolidate, Liraglutide Plans On Course

 
• By Anju Ghangurde

Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.

Biocon expects b(Humira) market to consolidate • Source: Shutterstock

More from Earnings

More from Business